Floatz logo

Rondecabtagene Autoleucel

Lymphoma, B-Cell

Lyell Immunopharma, Inc.Cell therapyPhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
73/ 100

Competitive context

316 Active assets in the Lymphoma, B-Cell cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Rondecabtagene Autoleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
large B-cell lymphomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →